Table 1. Patients’ Characteristics and the Adjuvant Treatment Received.
| PD group (n = 52) | Control Group (n = 700) | Matched Group (n = 156) | |||
| Significanceξ | Significanceξ | ||||
| Age | P = 0.87 | P = 0.42 | |||
| ≥50 | 27 (51.9%) | 372 (53.1%) | 71 (45.5%) | ||
| <50 | 25 (48.1%) | 328 (46.9%) | 85 (54.5%) | ||
| Dimension | P<0.01 | / | |||
| ≤2 cm | 17 (32.7%) | 423 (60.4%) | 51 (32.7%) | ||
| >2 cm | 35 (67.3%) | 275 (39.3%) | 105 (67.3%) | ||
| unknown | 2 (0.3%) | ||||
| Grade | P = 0.01 | P = 0.63 | |||
| I | 4 (7.7%) | 120 (17.1%) | 17 (10.9%) | ||
| II | 21 (40.4%) | 355 (50.7%) | 53 (34.0%) | ||
| III | 27 (51.9%) | 225 (32.1%) | 86 (55.1%) | ||
| ALN | P<0.01 | / | |||
| positive | 28 (53.8%) | 250 (35.7%) | 84 (53.8%) | ||
| negative | 24 (46.2%) | 450 (64.3%) | 72 (46.2%) | ||
| Hormone Receptor | P<0.01 | / | |||
| positive | 18 (34.6%) | 488 (69.7%) | 54 (34.6%) | ||
| negative | 34 (65.4%) | 212 (30.3%) | 102 (65.4%) | ||
| Her2 | P<0.01 | / | |||
| positive | 40 (76.9%) | 149 (21.3%) | 120 (76.9%) | ||
| negative | 12 (23.1%) | 551 (78.7%) | 36 (23.1%) | ||
| Chemotherapy | P = 0.02 | P = 0.85 | |||
| None | 7 (13.5%) | 151 (21.6%) | 19 (12.2%) | ||
| CMF | 4 (7.7%) | 93 (13.3%) | 15 (9.6%) | ||
| Anthracycline- based | 29 (55.7%) | 376 (53.7%) | 78 (50.0%) | ||
| Taxane-based | 12 (23.1%) | 68 (9.7%) | 42 (26.9%) | ||
| Unkown | 0 | 12 (1.7%) | 2 (1.3%) | ||
| Radiation | P<0.01 | P = 0.62 | |||
| No | 22 (42.3%) | 445 (63.6%) | 59 (37.8%) | ||
| Yes | 30 (57.7%) | 238 (34%) | 95 (60.9%) | ||
| Unkown | 0 | 17 (2.4%) | 2 (1.3%) | ||
| Endocrine Therapy | P<0.01 | P = 0.93 | |||
| No | 34 (65.4%) | 212 (30.3%) | 103 (66.0%) | ||
| Yes | 18 (34.6%) | 480 (68.6%) | 53 (33.9%) | ||
| Unkown | 0 | 8 (1.1%) | 0 | ||
| Target Therapy | P = 0.02 | P = 0.82 | |||
| No | 50 (96.2%) | 695 (99.3%) | 151 (96.8%) | ||
| Yes | 2 (3.8%) | 5 (0.7%) | 5 (3.2%) | ||
ξ
Compared with PD group.